Inherited Metabolic Disorders: From Bench to Bedside

Inherited metabolic disorders (IMDs), commonly referred to as inborn errors of metabolism, represent a spectrum of disorders with a defined (or presumed) primary genetic cause which disrupts the normal metabolism of essential molecules in the body [...].

• Publication year

  2024

• Venue

  Biomedicines

• Publication date

  2024-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/biomedicines12010174PMID 38255278PMCID 10813142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Broad Characterization of Glycogen Storage Disease IV Patients: A Clinical, Genetic, and Histopathological Study

  2023cited by this paper
• The Biology of Lysosomes: From Order to Disorder

  2023cited by this paper
• N-Glycoprofiling of SLC35A2-CDG: Patient with a Novel Hemizygous Variant

  2023cited by this paper
• Leukocyte Imbalances in Mucopolysaccharidoses Patients

  2023cited by this paper
• Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?

  2022cited by this paper
• An international classification of inherited metabolic disorders (ICIMD)

  2020cited by this paper
• Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin

  2019cited by this paper
• The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.

  2018cited by this paper
• Lysosomal storage diseases

  2018cited by this paper
• From Lysosomal Storage Diseases to NKT Cell Activation and Back

  2017cited by this paper
• Clinical prodromes of neurodegeneration in Anderson-Fabry disease

  2015cited by this paper
• Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice

  2014cited by this paper
• Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.

  2012cited by this paper
• The link between the GBA gene and parkinsonism.

  2012cited by this paper
• Glycosaminoglycan Storage Disorders: A Review

  2011cited by this paper
• Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease.

  2008cited by this paper
• The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells

  2007cited by this paper
• Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism

  2007cited by this paper
• The incidence of inherited metabolic disorders in the West Midlands, UK

  2006cited by this paper
• Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases

  2006cited by this paper
• Parkinsonism and Anderson Fabry's disease: A case report

  2006cited by this paper
• Cutting Edge: Impaired Glycosphingolipid Trafficking and NKT Cell Development in Mice Lacking Niemann-Pick Type C1 Protein1

  2006cited by this paper
• [An autopsied case of Fabry's disease presenting with parkinsonism and cardiomegaly as a cardinal clinical manifestation].

  1994cited by this paper
• Lysosomal storage diseases.

  1986cited by this paper

• Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications

  2025cites this paper